Adjuvant Pelvic Intensity Modulated Radiation Therapy and Concurrent Docetaxel and Cisplatin Chemotherapy for Postoperative Cervical Cancer With Adverse Risk Factors: A Retrospective Report on Toxicity and Outcomes

Abstract

Retrospectively, to assess the toxicity of delivering postoperative pelvic intensity-modulated radiation therapy (IMRT) and concurrent docetaxel and cisplatin chemotherapy for cervical cancer patients with adverse risk factors. We began by exploring the feasibility of reducing ovarian toxicity and evaluated the variation of ovarian function in patients with ovarian transposition.